Gliclapack MV 0.2mg/500mg/80mg Tablet
Marketer
Koye Pharmaceuticals Pvt ltd
Salt Composition
Voglibose (0.2mg) + Metformin (500mg) + Gliclazide (80mg)
Overview Gliclapack MV 0.2mg/500mg/80mg Tablet
Diabexe Trio 0.2mg/500mg/80mg tablets are classified as antidiabetic medications, combining drugs to manage type 2 diabetes in adults. This formulation assists in regulating blood glucose. Diabexe Trio should be administered with food, consistently at the same time daily for optimal effectiveness. Dosage is determined by your physician and may be adjusted based on blood sugar monitoring. Continued use is crucial, even with controlled blood sugar, as abrupt cessation can elevate glucose levels, potentially causing kidney complications, vision impairment, neuropathy, and limb loss. This medication is part of a comprehensive diabetes management plan including diet, exercise, and weight management as directed by your doctor. Lifestyle choices significantly impact diabetes control. Hypoglycemia (low blood sugar) is a prevalent side effect, characterized by sweating, dizziness, headache, and tremors. Regular meals and readily available glucose sources (e.g., sugary snacks or juice) are essential. Alcohol consumption should be minimized due to its hypoglycemic risk. Additional potential side effects include altered taste, nausea, vomiting, diarrhea, abdominal pain, headache, edema, blurred vision, bone fractures, and weight gain. This medication is contraindicated for type 1 diabetes, diabetic ketoacidosis, or severe hepatic or renal impairment. Prior heart disease should be disclosed to your physician before commencing treatment. Consult your doctor before use during pregnancy or breastfeeding. Regular blood glucose monitoring, along with potential blood tests for cell counts and liver function, are recommended.
Primary Ingredients of Gliclapack MV 0.2mg/500mg/80mg Tablet
No text was provided to rewrite.
Uses of Gliclapack MV 0.2mg/500mg/80mg Tablet
Managing type 2 diabetes
Major Benefits of Gliclapack MV 0.2mg/500mg/80mg Tablet:
Administer this medication precisely as prescribed by your physician, adhering to the recommended dosage and treatment schedule. Ingest the Gliclapack MV 0.2mg/500mg/80mg tablet whole; avoid chewing, crushing, or fracturing it. Consume this medication with a meal.
Common Side effects of Gliclapack MV 0.2mg/500mg/80mg Tablet:
- Nausea
- Hypoglycemia (low blood glucose level)
- Abdominal pain
- Constipation
How to use Gliclapack MV 0.2mg/500mg/80mg Tablet:
Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and timeframe. Ingest the Gliclapack MV 0.2mg/500mg/80mg tablet whole; avoid chewing, crushing, or fracturing it. Administer this medication with food.
How Gliclapack MV 0.2mg/500mg/80mg Tablet works:
Each Gliclapack MV tablet (0.2mg/500mg/80mg) combines three distinct antidiabetic agents.
SAFETY ADVICE
AlcoholUNSAFE
Combining Gliclapack MV 0.2mg/500mg/80mg tablets with alcohol is inadvisable.
PregnancyCONSULT YOUR DOCTOR
Using Gliclapack MV 0.2mg/500mg/80mg tablets during pregnancy might pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the advantages against possible dangers prior to prescribing. Seek medical advice.
Breast feedingCAUTION
The use of Gliclapack MV 0.2mg/500mg/80mg tablets while breastfeeding requires careful consideration. Mothers should discontinue breastfeeding for the duration of their treatment and until the medication is fully cleared from their system.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.
KidneyCAUTION
Patients with kidney impairment should use Gliclapack MV 0.2mg/500mg/80mg tablets cautiously, potentially requiring dosage modification. Consult your physician. This medication is contraindicated in patients with severe kidney disease. Regular monitoring of kidney function is recommended during treatment.
LiverCAUTION
Patients with liver disease should use Gliclapack MV 0.2mg/500mg/80mg Tablets cautiously, potentially requiring dosage modification. A physician's consultation is advised. Low initial doses are typically prescribed for individuals with mild to moderate liver impairment; however, the medication is contraindicated in those with severe liver disease.
What if you forget to take Gliclapack MV 0.2mg/500mg/80mg Tablet :
NA
Facts to Know About Gliclapack MV 0.2mg/500mg/80mg Tablet
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Treatment |
3,018 People bought this recently